CC-5013 and Rituximab in Waldenstrom's Macroglobulinemia
This study has been completed.
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Celgene Corporation
Genentech
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00142168
First received: September 1, 2005
Last updated: June 23, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2008 |
| Primary Completion Date: | May 2006 (Final data collection date for primary outcome measure) |